デフォルト表紙
市場調査レポート
商品コード
997871

小児用医薬品およびワクチンの世界市場

Pediatric Drugs and Vaccines

出版日: | 発行: Global Industry Analysts, Inc. | ページ情報: 英文 240 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=110.22円

ご注意:Single user licenseはDRM(デジタル著作権管理システム)付PDFとなります。
PDFの閲覧には Adobe Digital Editions (無償)のインストールが必要となります。
認証されたPC上のみでの閲覧と、1回のプリントアウトが可能となっております。

小児用医薬品およびワクチンの世界市場
出版日: 2021年04月01日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 240 Pages
納期: 即日から翌営業日
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

世界の小児用医薬品およびワクチンの市場規模は、分析期間(2020年~2027年)に5.8%のCAGRで成長する見通しで、2020年の1,001億米ドルから、2027年には1,488億米ドルに達すると予測されています。

当レポートで分析されているセグメントの1つである抗生物質は、分析期間中に5.9%のCAGRで成長し、368億米ドルに達すると予測されています。

当レポートは、世界の小児用医薬品およびワクチン市場について調査しており、市場シェア、Covid-19の影響、動向や成長要因、地域別の市場分析、競合情勢、主要企業のプロファイル等の情報を提供しています。

調査対象企業の例

  • Abbott Laboratories
  • Allergan Inc.
  • Amgen Inc.
  • AstraZeneca Plc
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Genentech Inc.
  • GlaxoSmithKline Plc
  • Janssen Biologics B.V
  • Merck & Co. Inc.
  • Novartis AG
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Sanofi
  • Shionogi Inc.
  • Shire Pharmaceuticals Group Plc

目次

I. 調査手法

II. エグゼクティブサマリー

  • 市場概要
    • インフルエンサー市場の洞察
    • 世界市場の軌跡
    • 小児科:十分なサービスが受けられず、過小評価されているグループ
    • 最近の市場活動
    • 小児用医薬品市場-機会の宝庫
    • 米国:小児用医薬品およびワクチンの最大の市場
    • より速い成長が見られる新興国市場
    • 抗生物質:最も売れている医薬品クラス
    • 小児用ワクチン市場-高成長軌道上
    • 世界のワクチン市場の需要と供給の動向
    • ユニセフによるBCGワクチンの供給不足への対処
    • ワクチンインデックスへのアクセス:ワクチンへのアクセス向上の支援
    • 小児用ワクチン分野における最近の進歩/成果
    • Covid-19の影響と迫り来る世界の景気後退
  • 主要企業
    • Abbott Laboratories (米国)
    • Allergan, Inc. (米国)
    • Amgen, Inc. (米国)
    • AstraZeneca Plc. (英国)
    • Boehringer Ingelheim GmbH (ドイツ)
    • Bristol-Myers Squibb Company (米国)
    • Eli Lilly and Company (米国)
    • F. Hoffmann-La Roche Ltd (スイス)
    • Genentech, Inc. (米国)
    • GlaxoSmithKline plc. (英国)
    • Janssen Biologics B.V. (米国)
    • Actelion Pharmaceuticals Ltd (スイス) (A Janssen Pharmaceutical Company)
    • Merck & Co., Inc. (米国)
    • Novartis AG (スイス)
    • Novo Nordisk A/S (デンマーク)
    • Pfizer, Inc. (米国)
    • Sanofi S.A (France)
    • Shionogi Inc. (米国)
    • Shire Pharmaceuticals Group Plc. (英国)
  • 動向と推進要因
    • メーカーの関心を高める小児科の独占性
    • ブランド薬に付与された小児科の独占権
    • 新製品の承認とパイプライン-主な成長要因
    • 最近の小児用医薬品の承認:2015-2017
    • 小児用医薬品の承認:2011-2014
    • フェーズIII完成小児用医薬品:2015-2017(2017年7月時点)
    • 進行中のフェーズIII小児用医薬品の臨床試験:2015年から2017年(2017年7月時点)
    • 肥満関連の小児用医薬品の可能性
    • うっ血性心不全治療の小児用医薬品のリスト
    • 子供の命を救うのに役立つ最近の調査結果
    • 小児用医薬品開発の課題:製剤の問題と臨床試験の倫理的制約
    • 製薬企業が専用の小児試験を実施するための金銭的誘惑
    • モデリングとシミュレーション-小児臨床研究スポンサーのための強力なツール
    • ファーマコメトリクスのアプローチは、米国とEUの研究者の間で牽引力を獲得します
    • ファーマコメトリアプローチの採用に関連する課題
    • 倫理的に正しい臨床試験を実施するためのガイドライン
    • 小児用医薬品市場-適応外処方は正当化されるか?
    • インドの製薬企業が肺炎球菌結合型ワクチンを開発
    • 高い予防接種費用:肺炎球菌予防接種の主な障害
    • 保護者によるワクチン拒否-米国市場での成長傾向
    • 人気を博す小児用希少疾病用医薬品
    • FDA承認の希少疾病用医薬品のリスト:2015-2016
    • FDA指定希少疾病用医薬品のリスト:2015-2017
    • 希少な小児用医薬品の革新を促進する小児レビューバウチャー
    • 小児HIV感染症の固定用量の組み合わせにさらに焦点を当てる必要性
    • HIV治療のために承認された小児抗レトロウイルス薬
    • 高度に断片化された成長ホルモン市場
  • 世界市場の見通し

III. 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

IV. 競合

  • 企業プロファイル:90社
目次
Product Code: MCP-6503

Abstract:

Global Pediatric Drugs and Vaccines Market to Reach $148.8 Billion by 2027

Amid the COVID-19 crisis, the global market for Pediatric Drugs and Vaccines estimated at US$100.1 Billion in the year 2020, is projected to reach a revised size of US$148.8 Billion by 2027, growing at a CAGR of 5.8% over the analysis period 2020-2027. Antibiotics, one of the segments analyzed in the report, is projected to record a 5.9% CAGR and reach US$36.8 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Vaccines segment is readjusted to a revised 6.8% CAGR for the next 7-year period.

The U.S. Market is Estimated at $27.1 Billion, While China is Forecast to Grow at 8.9% CAGR

The Pediatric Drugs and Vaccines market in the U.S. is estimated at US$27.1 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$31.4 Billion by the year 2027 trailing a CAGR of 8.9% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 3.2% and 5.2% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 3.7% CAGR.

Allergy & Respiratory Segment to Record 4.3% CAGR

In the global Allergy & Respiratory segment, USA, Canada, Japan, China and Europe will drive the 3.9% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$14.1 Billion in the year 2020 will reach a projected size of US$18.4 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$20.1 Billion by the year 2027, while Latin America will expand at a 5.3% CAGR through the analysis period.

Select Competitors (Total 90 Featured) -

  • Abbott Laboratories
  • Allergan Inc.
  • Amgen Inc.
  • AstraZeneca Plc
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Genentech Inc.
  • GlaxoSmithKline Plc
  • Janssen Biologics B.V
  • Merck & Co. Inc.
  • Novartis AG
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Sanofi
  • Shionogi Inc.
  • Shire Pharmaceuticals Group Plc

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Pediatrics: A Highly Underserved and Undervalued Group
    • Recent Market Activity
    • Pediatric Drugs Market - An Abode of Opportunities
    • The United States: Largest Market for Pediatric Drugs and Vaccines
    • Developing Markets to Witness Faster Growth
    • Antibiotics: Largest Selling Drug Classes
    • Pediatric Vaccines Market - On High Growth Trajectory
    • Supply and Demand Dynamics of the Global Vaccine Market
    • UNICEF Addresses BCG Vaccine Supply Shortage
    • Access to Vaccines Index: Aiding Increased Access to Vaccines
    • Recent Advancements/Achievements in the Pediatric Vaccines Space
    • Impact of Covid-19 and a Looming Global Recession
  • 2. FOCUS ON SELECT PLAYERS
    • Abbott Laboratories (USA)
    • Allergan, Inc. (USA)
    • Amgen, Inc. (USA)
    • AstraZeneca Plc. (UK)
    • Boehringer Ingelheim GmbH (Germany)
    • Bristol-Myers Squibb Company (USA)
    • Eli Lilly and Company (USA)
    • F. Hoffmann-La Roche Ltd (Switzerland)
    • Genentech, Inc. (USA)
    • GlaxoSmithKline plc. (UK)
    • Janssen Biologics B.V. (USA)
    • Actelion Pharmaceuticals Ltd (Switzerland) (A Janssen Pharmaceutical Company)
    • Merck & Co., Inc. (USA)
    • Novartis AG (Switzerland)
    • Novo Nordisk A/S (Denmark)
    • Pfizer, Inc. (USA)
    • Sanofi S.A (France)
    • Shionogi Inc. (USA)
    • Shire Pharmaceuticals Group Plc. (UK)
  • 3. MARKET TRENDS & DRIVERS
    • Pediatric Exclusivity Drives Manufacturers' Interest
    • Pediatric Exclusitivity Granted to Branded Drugs
    • New Product Approvals and Pipeline - A Key Growth Propeller
    • Recent Pediatric Drug Approvals: 2015-2017
    • Pediatric Drug Approvals: 2011-2014
    • Phase III Completed Pediatric Drugs: 2015-2017 (As of July 2017)
    • Ongoing Phase III Pediatric Drugs Clinical Trials: 2015-2017 (As of July 2017)
    • Potential for Pediatric Drugs Against Obesity-related Conditions
    • List of Pediatric Drugs for Congestive Heart Failure Treatment
    • Recent Findings to Help Save Children's Lives
    • Challenges of Pediatric Drug Development: Formulation Problems and Ethical Constraints of Clinical Trials
    • Financial Enticement for Drug Makers to Conduct Dedicated Pediatric Trials
    • Modeling & Simulation - A Powerful Tool for Pediatric Clinical Study Sponsors
    • Pharmacometrics Approaches Gain Traction Among US and EU Researchers
    • Challenges Associated with Adoption of Pharmacometric Approach
    • Guidelines for Conducting Ethically Correct Clinical Trials
    • Pediatric Drug Market - Is Off-label Prescription Justified?
    • Indian Drug Manufacturers Develop Pneumococcal Conjugate Vaccine
    • High Vaccination Costs: A Major Hindrance for Pneumonia Vaccination
    • Vaccine Refusal by Parents - A Growing Trend in the US Market
    • Orphan Drugs for Pediatric Use Gain Popularity
    • List of FDA Approved Orphan Drugs: 2015-2016
    • List of FDA Designated Orphan Drugs: 2015-2017
    • Pediatric Review Vouchers Foster Innovation in Rare Pediatric Drugs
    • Need for Higher Focus on Fixed-Dose Combination for Pediatric HIV Infections
    • Approved Pediatric Antiretroviral Drugs for HIV Treatment
    • Highly Fragmented Growth Hormone Market
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Current & Future Analysis for Pediatric Drugs and Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 2: World Historic Review for Pediatric Drugs and Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 3: World 15-Year Perspective for Pediatric Drugs and Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2012, 2020 & 2027
    • TABLE 4: World Current & Future Analysis for Antibiotics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 5: World Historic Review for Antibiotics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 6: World 15-Year Perspective for Antibiotics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 7: World Current & Future Analysis for Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 8: World Historic Review for Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 9: World 15-Year Perspective for Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 10: World Current & Future Analysis for Allergy & Respiratory by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 11: World Historic Review for Allergy & Respiratory by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 12: World 15-Year Perspective for Allergy & Respiratory by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 13: World Current & Future Analysis for CNS by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 14: World Historic Review for CNS by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 15: World 15-Year Perspective for CNS by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 16: World Current & Future Analysis for Hormones by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 17: World Historic Review for Hormones by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 18: World 15-Year Perspective for Hormones by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 19: World Current & Future Analysis for Other Therapeutic Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 20: World Historic Review for Other Therapeutic Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 21: World 15-Year Perspective for Other Therapeutic Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027

III. MARKET ANALYSIS

  • UNITED STATES
    • TABLE 22: USA Current & Future Analysis for Pediatric Drugs and Vaccines by Therapeutic Class - Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 23: USA Historic Review for Pediatric Drugs and Vaccines by Therapeutic Class - Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 24: USA 15-Year Perspective for Pediatric Drugs and Vaccines by Therapeutic Class - Percentage Breakdown of Value Sales for Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes for the Years 2012, 2020 & 2027
  • CANADA
    • TABLE 25: Canada Current & Future Analysis for Pediatric Drugs and Vaccines by Therapeutic Class - Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 26: Canada Historic Review for Pediatric Drugs and Vaccines by Therapeutic Class - Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 27: Canada 15-Year Perspective for Pediatric Drugs and Vaccines by Therapeutic Class - Percentage Breakdown of Value Sales for Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes for the Years 2012, 2020 & 2027
  • JAPAN
    • TABLE 28: Japan Current & Future Analysis for Pediatric Drugs and Vaccines by Therapeutic Class - Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 29: Japan Historic Review for Pediatric Drugs and Vaccines by Therapeutic Class - Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 30: Japan 15-Year Perspective for Pediatric Drugs and Vaccines by Therapeutic Class - Percentage Breakdown of Value Sales for Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes for the Years 2012, 2020 & 2027
  • CHINA
    • TABLE 31: China Current & Future Analysis for Pediatric Drugs and Vaccines by Therapeutic Class - Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 32: China Historic Review for Pediatric Drugs and Vaccines by Therapeutic Class - Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 33: China 15-Year Perspective for Pediatric Drugs and Vaccines by Therapeutic Class - Percentage Breakdown of Value Sales for Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes for the Years 2012, 2020 & 2027
  • EUROPE
    • TABLE 34: Europe Current & Future Analysis for Pediatric Drugs and Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 35: Europe Historic Review for Pediatric Drugs and Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 36: Europe 15-Year Perspective for Pediatric Drugs and Vaccines by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2012, 2020 & 2027
    • TABLE 37: Europe Current & Future Analysis for Pediatric Drugs and Vaccines by Therapeutic Class - Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 38: Europe Historic Review for Pediatric Drugs and Vaccines by Therapeutic Class - Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 39: Europe 15-Year Perspective for Pediatric Drugs and Vaccines by Therapeutic Class - Percentage Breakdown of Value Sales for Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes for the Years 2012, 2020 & 2027
  • FRANCE
    • TABLE 40: France Current & Future Analysis for Pediatric Drugs and Vaccines by Therapeutic Class - Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 41: France Historic Review for Pediatric Drugs and Vaccines by Therapeutic Class - Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 42: France 15-Year Perspective for Pediatric Drugs and Vaccines by Therapeutic Class - Percentage Breakdown of Value Sales for Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes for the Years 2012, 2020 & 2027
  • GERMANY
    • TABLE 43: Germany Current & Future Analysis for Pediatric Drugs and Vaccines by Therapeutic Class - Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 44: Germany Historic Review for Pediatric Drugs and Vaccines by Therapeutic Class - Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 45: Germany 15-Year Perspective for Pediatric Drugs and Vaccines by Therapeutic Class - Percentage Breakdown of Value Sales for Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes for the Years 2012, 2020 & 2027
  • ITALY
    • TABLE 46: Italy Current & Future Analysis for Pediatric Drugs and Vaccines by Therapeutic Class - Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 47: Italy Historic Review for Pediatric Drugs and Vaccines by Therapeutic Class - Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 48: Italy 15-Year Perspective for Pediatric Drugs and Vaccines by Therapeutic Class - Percentage Breakdown of Value Sales for Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes for the Years 2012, 2020 & 2027
  • UNITED KINGDOM
    • TABLE 49: UK Current & Future Analysis for Pediatric Drugs and Vaccines by Therapeutic Class - Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 50: UK Historic Review for Pediatric Drugs and Vaccines by Therapeutic Class - Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 51: UK 15-Year Perspective for Pediatric Drugs and Vaccines by Therapeutic Class - Percentage Breakdown of Value Sales for Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes for the Years 2012, 2020 & 2027
  • SPAIN
    • TABLE 52: Spain Current & Future Analysis for Pediatric Drugs and Vaccines by Therapeutic Class - Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 53: Spain Historic Review for Pediatric Drugs and Vaccines by Therapeutic Class - Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 54: Spain 15-Year Perspective for Pediatric Drugs and Vaccines by Therapeutic Class - Percentage Breakdown of Value Sales for Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes for the Years 2012, 2020 & 2027
  • RUSSIA
    • TABLE 55: Russia Current & Future Analysis for Pediatric Drugs and Vaccines by Therapeutic Class - Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 56: Russia Historic Review for Pediatric Drugs and Vaccines by Therapeutic Class - Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 57: Russia 15-Year Perspective for Pediatric Drugs and Vaccines by Therapeutic Class - Percentage Breakdown of Value Sales for Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes for the Years 2012, 2020 & 2027
  • REST OF EUROPE
    • TABLE 58: Rest of Europe Current & Future Analysis for Pediatric Drugs and Vaccines by Therapeutic Class - Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 59: Rest of Europe Historic Review for Pediatric Drugs and Vaccines by Therapeutic Class - Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 60: Rest of Europe 15-Year Perspective for Pediatric Drugs and Vaccines by Therapeutic Class - Percentage Breakdown of Value Sales for Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes for the Years 2012, 2020 & 2027
  • ASIA-PACIFIC
    • TABLE 61: Asia-Pacific Current & Future Analysis for Pediatric Drugs and Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 62: Asia-Pacific Historic Review for Pediatric Drugs and Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 63: Asia-Pacific 15-Year Perspective for Pediatric Drugs and Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2012, 2020 & 2027
    • TABLE 64: Asia-Pacific Current & Future Analysis for Pediatric Drugs and Vaccines by Therapeutic Class - Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 65: Asia-Pacific Historic Review for Pediatric Drugs and Vaccines by Therapeutic Class - Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 66: Asia-Pacific 15-Year Perspective for Pediatric Drugs and Vaccines by Therapeutic Class - Percentage Breakdown of Value Sales for Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes for the Years 2012, 2020 & 2027
  • AUSTRALIA
    • TABLE 67: Australia Current & Future Analysis for Pediatric Drugs and Vaccines by Therapeutic Class - Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 68: Australia Historic Review for Pediatric Drugs and Vaccines by Therapeutic Class - Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 69: Australia 15-Year Perspective for Pediatric Drugs and Vaccines by Therapeutic Class - Percentage Breakdown of Value Sales for Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes for the Years 2012, 2020 & 2027
  • INDIA
    • TABLE 70: India Current & Future Analysis for Pediatric Drugs and Vaccines by Therapeutic Class - Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 71: India Historic Review for Pediatric Drugs and Vaccines by Therapeutic Class - Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 72: India 15-Year Perspective for Pediatric Drugs and Vaccines by Therapeutic Class - Percentage Breakdown of Value Sales for Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes for the Years 2012, 2020 & 2027
  • SOUTH KOREA
    • TABLE 73: South Korea Current & Future Analysis for Pediatric Drugs and Vaccines by Therapeutic Class - Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 74: South Korea Historic Review for Pediatric Drugs and Vaccines by Therapeutic Class - Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 75: South Korea 15-Year Perspective for Pediatric Drugs and Vaccines by Therapeutic Class - Percentage Breakdown of Value Sales for Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes for the Years 2012, 2020 & 2027
  • REST OF ASIA-PACIFIC
    • TABLE 76: Rest of Asia-Pacific Current & Future Analysis for Pediatric Drugs and Vaccines by Therapeutic Class - Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 77: Rest of Asia-Pacific Historic Review for Pediatric Drugs and Vaccines by Therapeutic Class - Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 78: Rest of Asia-Pacific 15-Year Perspective for Pediatric Drugs and Vaccines by Therapeutic Class - Percentage Breakdown of Value Sales for Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes for the Years 2012, 2020 & 2027
  • LATIN AMERICA
    • TABLE 79: Latin America Current & Future Analysis for Pediatric Drugs and Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 80: Latin America Historic Review for Pediatric Drugs and Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 81: Latin America 15-Year Perspective for Pediatric Drugs and Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2012, 2020 & 2027
    • TABLE 82: Latin America Current & Future Analysis for Pediatric Drugs and Vaccines by Therapeutic Class - Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 83: Latin America Historic Review for Pediatric Drugs and Vaccines by Therapeutic Class - Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 84: Latin America 15-Year Perspective for Pediatric Drugs and Vaccines by Therapeutic Class - Percentage Breakdown of Value Sales for Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes for the Years 2012, 2020 & 2027
  • ARGENTINA
    • TABLE 85: Argentina Current & Future Analysis for Pediatric Drugs and Vaccines by Therapeutic Class - Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 86: Argentina Historic Review for Pediatric Drugs and Vaccines by Therapeutic Class - Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 87: Argentina 15-Year Perspective for Pediatric Drugs and Vaccines by Therapeutic Class - Percentage Breakdown of Value Sales for Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes for the Years 2012, 2020 & 2027
  • BRAZIL
    • TABLE 88: Brazil Current & Future Analysis for Pediatric Drugs and Vaccines by Therapeutic Class - Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 89: Brazil Historic Review for Pediatric Drugs and Vaccines by Therapeutic Class - Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 90: Brazil 15-Year Perspective for Pediatric Drugs and Vaccines by Therapeutic Class - Percentage Breakdown of Value Sales for Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes for the Years 2012, 2020 & 2027
  • MEXICO
    • TABLE 91: Mexico Current & Future Analysis for Pediatric Drugs and Vaccines by Therapeutic Class - Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 92: Mexico Historic Review for Pediatric Drugs and Vaccines by Therapeutic Class - Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 93: Mexico 15-Year Perspective for Pediatric Drugs and Vaccines by Therapeutic Class - Percentage Breakdown of Value Sales for Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes for the Years 2012, 2020 & 2027
  • REST OF LATIN AMERICA
    • TABLE 94: Rest of Latin America Current & Future Analysis for Pediatric Drugs and Vaccines by Therapeutic Class - Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 95: Rest of Latin America Historic Review for Pediatric Drugs and Vaccines by Therapeutic Class - Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 96: Rest of Latin America 15-Year Perspective for Pediatric Drugs and Vaccines by Therapeutic Class - Percentage Breakdown of Value Sales for Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes for the Years 2012, 2020 & 2027
  • MIDDLE EAST
    • TABLE 97: Middle East Current & Future Analysis for Pediatric Drugs and Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 98: Middle East Historic Review for Pediatric Drugs and Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 99: Middle East 15-Year Perspective for Pediatric Drugs and Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2012, 2020 & 2027
    • TABLE 100: Middle East Current & Future Analysis for Pediatric Drugs and Vaccines by Therapeutic Class - Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 101: Middle East Historic Review for Pediatric Drugs and Vaccines by Therapeutic Class - Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 102: Middle East 15-Year Perspective for Pediatric Drugs and Vaccines by Therapeutic Class - Percentage Breakdown of Value Sales for Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes for the Years 2012, 2020 & 2027
  • IRAN
    • TABLE 103: Iran Current & Future Analysis for Pediatric Drugs and Vaccines by Therapeutic Class - Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 104: Iran Historic Review for Pediatric Drugs and Vaccines by Therapeutic Class - Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 105: Iran 15-Year Perspective for Pediatric Drugs and Vaccines by Therapeutic Class - Percentage Breakdown of Value Sales for Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes for the Years 2012, 2020 & 2027
  • ISRAEL
    • TABLE 106: Israel Current & Future Analysis for Pediatric Drugs and Vaccines by Therapeutic Class - Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 107: Israel Historic Review for Pediatric Drugs and Vaccines by Therapeutic Class - Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 108: Israel 15-Year Perspective for Pediatric Drugs and Vaccines by Therapeutic Class - Percentage Breakdown of Value Sales for Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes for the Years 2012, 2020 & 2027
  • SAUDI ARABIA
    • TABLE 109: Saudi Arabia Current & Future Analysis for Pediatric Drugs and Vaccines by Therapeutic Class - Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 110: Saudi Arabia Historic Review for Pediatric Drugs and Vaccines by Therapeutic Class - Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 111: Saudi Arabia 15-Year Perspective for Pediatric Drugs and Vaccines by Therapeutic Class - Percentage Breakdown of Value Sales for Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes for the Years 2012, 2020 & 2027
  • UNITED ARAB EMIRATES
    • TABLE 112: UAE Current & Future Analysis for Pediatric Drugs and Vaccines by Therapeutic Class - Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 113: UAE Historic Review for Pediatric Drugs and Vaccines by Therapeutic Class - Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 114: UAE 15-Year Perspective for Pediatric Drugs and Vaccines by Therapeutic Class - Percentage Breakdown of Value Sales for Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes for the Years 2012, 2020 & 2027
  • REST OF MIDDLE EAST
    • TABLE 115: Rest of Middle East Current & Future Analysis for Pediatric Drugs and Vaccines by Therapeutic Class - Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 116: Rest of Middle East Historic Review for Pediatric Drugs and Vaccines by Therapeutic Class - Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 117: Rest of Middle East 15-Year Perspective for Pediatric Drugs and Vaccines by Therapeutic Class - Percentage Breakdown of Value Sales for Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes for the Years 2012, 2020 & 2027
  • AFRICA
    • TABLE 118: Africa Current & Future Analysis for Pediatric Drugs and Vaccines by Therapeutic Class - Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 119: Africa Historic Review for Pediatric Drugs and Vaccines by Therapeutic Class - Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 120: Africa 15-Year Perspective for Pediatric Drugs and Vaccines by Therapeutic Class - Percentage Breakdown of Value Sales for Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes for the Years 2012, 2020 & 2027

IV. COMPETITION

  • Total Companies Profiled: 90